- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Elevation Oncology Inc.
Headquarters: New York, NY, United States of America
Website: https://elevationoncology.com/...
Year Founded: 2019
Status: Public
Industry Sector: HealthTechnology
CEO: Joseph J. Ferra, Jr., MBA
Number Of Employees: 34
Enterprise Value: $-29,826,830
PE Ratio: -0.62
Exchange/Ticker 1: NASDAQ:ELEV
Exchange/Ticker 2: N/A
Latest Market Cap: $29,519,100
BioCentury | Feb 1, 2025
Management Tracks
Daiichi Sankyo to promote Okuzawa to CEO
Plus: New chair at Outlook and an update from Elevation
BioCentury | Jun 21, 2024
Management Tracks
ITM names Cavey CEO, plus PureTech, Brainstorm and more
Plus: New chairs for PureTech, Evexta and updates from PharmaEssentia, Brainstorm, Danaher and more
BioCentury | Nov 9, 2023
Deals
China’s strength is innovation on innovation. Western partners are lining up
Deep antibody expertise is a platform for leaps in new assets and technologies as Asia biotechs become increasingly competitive
BioCentury | Aug 24, 2023
Finance
Rapport, Fore join 2023’s list of crossover-backed biotechs
At least five biotechs have banked crossover rounds of at least $75M this month
BioCentury | May 26, 2023
Product Development
May 26 ASCO Quick Takes: BMS’s Reblozyl headed for SOC in first-line MDS
Plus: Zentalis’ azenosertib shows early promise in ovarian cancer, and updates from PDS and Elevation
BioCentury | Jan 7, 2023
Deals
Jan. 6 Quick Takes: Pfizer ‘externalizing’ some cancer, rare disease programs
Plus: Column Group leads Synthekine’s $100M series C, and updates from Amolyt, Perceive, bluebird bio, BioNTech and more
BioCentury | Nov 21, 2022
Data Byte
Signs Western companies are turning to China for cancer innovation
Over half of the cancer therapies Chinese companies out-licensed in 2021-22 employ new modalities or unapproved targets
BioCentury | Aug 10, 2022
Data Byte
Valuing ADC licensing deals
As data roll in for clinical ADCs licensed since 2020, upfront payments for preclinical deals show signs of growth
BioCentury | Jul 28, 2022
Finance
July 28 Quick Takes: Merck to expand Keytruda’s reach as sales top $5B
Plus venture rounds for BridGene, Ozette and updates from argenx, Elevation-CSPC and more
BioCentury | Jun 4, 2022
Product Development
New modalities give HER3 another shot at ASCO
ASCO data from Daiichi, Merus show anti-HER3 efficacy in challenging indications
Items per page:
1 - 10 of 17